In this episode of The Promise of Personalized Medicine, Perry sits down with Dr. Ryan Nelson, to explore the evolving and sometimes misunderstood world of personalized medicine. 

With years of hands-on experience, Dr. Nelson offers a refreshingly nuanced definition—one that goes beyond genetics to include biomarkers, digital tools, and system-wide collaboration for predictive, preventative, and precisely tailored care.

We dive deep into:

• the challenges and slow adoption of pharmacogenetics in the U.S.
• the ethical and regulatory friction surrounding genetic testing
• why "genetic exceptionalism" may actually hinder progress
• the FDA’s shifting role to real-world cost savings data

Ryan also shares a behind-the-scenes look at MetaCensus, a new distributed platform designed to foster consensus among stakeholders through open-access, federated data—creating space for payers, providers, pharma, and regulators to weigh evidence transparently.

—-------

Stay connected with our host, Perry Dimas, here on LinkedIn!
📧 Interested in joining our medical director advisory group? Email us at [email protected]
🔗 Connect on LinkedIn: linkedin.com/company/accessdx